# Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma

> **NCT00886028** · PHASE2 · UNKNOWN · sponsor: **National Institute of Cancerología** · enrollment: 31 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** Liposomal doxorubicin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00886028
- **Lead sponsor:** National Institute of Cancerología
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-09
- **Primary completion:** 2009-04
- **Final completion:** 2009-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2009-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00886028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00886028, "Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00886028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*